Acquisition Footprint Lucas Research was acquired by Centricity Research in December 2023, signaling an expansion pathway and potential cross-sell opportunities for access to a larger network, shared trial mechanisms, and broader site access for enrollment capabilities.

Top Enroller Track Historically a globally-ranked top enroller in Diabetes and related metabolic trials, Lucas Research demonstrates strong patient recruitment expertise which can be leveraged to improve enrollment speed and study timelines for partner sponsors.

Clinical Breadth The site specializes in a wide range of conditions including Type 1 and Type 2 Diabetes, NASH, obesity, cardiovascular outcomes, liver and kidney diseases, and autoimmune conditions, providing cross-therapeutic access for multi-arm or platform trials.

Coastal Access Located in Morehead City, NC with a large 23,000 sq ft facility and a 50+ team, the site offers scalable operations, on-site coordination, and potential for efficient site activation in a region with growing health research demand.

Strategic Partnerships Past collaborations with hyperCORE International and integration into a major CRO network through Centricity indicate openness to partnership models, co-development of studies, and expanded sponsor reach through networked sites.